# Cyrus Therapeutics: Research, South Korea

> Cyrus Therapeutics: Cyrus Therapeutics is a biotechnology company based in Seoul, founded in 2019. Based in South Korea. Founded 2019.

Source: https://millionrounds.com/startup/cyrus-therapeutics (Millionrounds; every figure on the page links to its filing or article)

South Korea · [Research startup](https://millionrounds.com/companies)

# Cyrus Therapeutics

Cyrus Therapeutics is a biotechnology company based in Seoul, founded in 2019.

Funding reported Last round: Series B

Research South Korea

Company summary

- **Founded:** 2019 7 years old
- **Team:** 17 11 to 50 people
- **Funding reported:** 39B as listed, currency not stated
- **Last round:** Series B Jan 2022

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Cyrus Therapeutics has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Cyrus Therapeutics

Cyrus Therapeutics is a biotechnology company based in Seoul, founded in 2019.

The company focuses on discovering and developing small molecule medicines aimed at targeting "undruggable" proteins associated with cancer and chronic diseases that have significant unmet needs. With a team of 11-20 employees, Cyrus operates under the NAICS code 541714, specializing in biotechnology research. Cyrus has made notable advancements, including receiving IND approvals from the South Korean MFDS and the U.S. FDA for its product CYRS1542, an oral GSPT1 molecular glue degrader targeting neuroendocrine cancer. The company emphasizes innovative approaches, developing small molecule inhibitors, targeted protein degraders, and immuno-oncology agents. Its mission is to address challenging therapeutic targets in oncogenic pathways, aiming to improve treatment options for patients with chronic or life-threatening diseases.

## What company datasets say Cyrus Therapeutics raised

Funding, as reported

Reported in all **39B** in the source's currency

Rounds **2**

Last round **Series B**

Last round size **24.3M**

Last round date **Jan 2022**

Investors listed **7**

## The company, in detail

What they build

Known for

biotechnology research

Built with from their website

NAVER Apache Viewport Meta Microsoft Exchange Microsoft 365 Apps & Services Mobile Friendly Microsoft Exchange Online Microsoft 365 Apache HTTP Server Outlook

+2 more

Microsoft Email Providers Google Search Console

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 8731
- **Region:** Seoul
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/cyrus-therapeutics)

## Research in South Korea

Startups like it

- [**Galux** founded 2020 *Raised*](https://millionrounds.com/company/galux)
- [**ExoCoBio** founded 2017 *Raised*](https://millionrounds.com/company/exocobio)
- [**iN Therapeutics** Yongin-si · founded 2020](https://millionrounds.com/startup/in-therapeutics)
- [**Mitoimmune Therapeutics Inc.** Seoul · founded 2018](https://millionrounds.com/startup/mitoimmune-therapeutics-inc)
- [**G+FLAS Life Sciences, Inc.** Seoul · founded 2014](https://millionrounds.com/startup/g-flas-life-sciences-inc)
- [**Dx & Vx** founded 2001](https://millionrounds.com/startup/dx-vx)
- [**Cellmeat** Seoul · founded 2019](https://millionrounds.com/startup/cellmeat)
- [**Bertis Inc** Seongnam-si · founded 2014](https://millionrounds.com/startup/bertis-inc)

## Is this your company?

Add your raise, your deck and your story, and put Cyrus Therapeutics in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)